Kamada Ltd. (NASDAQ:KMDA) hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $4.57 and last traded at $4.56, with a volume of 15,165 shares. The stock had previously closed at $4.48.

A number of brokerages have issued reports on KMDA. Zacks Investment Research upgraded Kamada from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a research note on Thursday, May 12th. TheStreet lowered Kamada from a “hold” rating to a “sell” rating in a research note on Thursday, June 9th.

The firm’s 50-day moving average price is $4.02 and its 200 day moving average price is $3.86. The stock’s market capitalization is $163.88 million.

Kamada (NASDAQ:KMDA) last released its earnings results on Tuesday, August 2nd. The company reported ($0.04) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.04). The company earned $19.10 million during the quarter, compared to analysts’ expectations of $18.50 million. Equities research analysts forecast that Kamada Ltd. will post ($0.11) EPS for the current year.

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.